Development Of Companion Diagnostics For ABSK091
29/04/2021 12:52
April 29 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK AND ABBISKO THERAPEUTICS ANNOUNCE STRATEGIC
PARTNERSHIP ON CO-DEVELOPMENT OF COMPANION DIAGNOSTICS FOR
ABSK091
Source text for Eikon: ID:nGNX1MD3gX
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer